AUSTRALIA-based AtCor has received its first order for its SphygmoCor system from China.
AtCor Medical develops and markets products for the early and non-invasive detection of cardiovascular risk and management of cardiovascular disease.
The SphygmoCor XCEL system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
The first order from the Chinese market came from AtCor's Chinese distributor, Angy (China) Medical. It consists of 11 systems, and follows the launch of the new product at the China International Medical Equipment Fair in Shenzhen in April 2014.
According to Duncan Ross, CEO and president of AtCor, the sale establishes a "beachhead" for the company in the Chinese market, just as the country's rising middle class is gaining a greater awareness of hypertension.
The SphygmoCor system measures central blood pressure, which according to clinical evidence is a stronger predictor of cardiovascular events than other measurement types.